163 related articles for article (PubMed ID: 12902856)
21. [Cyclooxygenase(COX)-2-inhibition in the prevention and treatment of colorectal carcinoma].
Tuynman JB; Hulscher JB; Steller EP; van Lanschot JJ; Richel DJ
Ned Tijdschr Geneeskd; 2003 Nov; 147(45):2207-12. PubMed ID: 14640057
[TBL] [Abstract][Full Text] [Related]
22. Prevention of colorectal cancer through the use of COX-2 selective inhibitors.
Peek RM
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S50-6. PubMed ID: 15309515
[TBL] [Abstract][Full Text] [Related]
23. The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors.
Stephens J; Laskin B; Pashos C; Peña B; Wong J
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii40-52. PubMed ID: 14585917
[TBL] [Abstract][Full Text] [Related]
24. [Analgesic effects of cyclooxygenase 2 inhibitors].
Jayr C
Bull Cancer; 2004 May; 91 Spec No():S125-31. PubMed ID: 15239341
[TBL] [Abstract][Full Text] [Related]
25. COX-2 inhibition as a tool to treat and prevent colorectal cancer.
Tuynman JB; Peppelenbosch MP; Richel DJ
Crit Rev Oncol Hematol; 2004 Nov; 52(2):81-101. PubMed ID: 15501074
[TBL] [Abstract][Full Text] [Related]
26. [Cyclooxygenase 2 inhibitors and lung carcinoma].
Spano JP; Chouahnia K; Morère JF
Bull Cancer; 2004 May; 91 Spec No():S109-12. PubMed ID: 15239338
[TBL] [Abstract][Full Text] [Related]
27. Cyclooxygenase-2 as a target for anticancer drug development.
Méric JB; Rottey S; Olaussen K; Soria JC; Khayat D; Rixe O; Spano JP
Crit Rev Oncol Hematol; 2006 Jul; 59(1):51-64. PubMed ID: 16531064
[TBL] [Abstract][Full Text] [Related]
28. NSAIDs and breast cancer: a possible prevention and treatment strategy.
Agrawal A; Fentiman IS
Int J Clin Pract; 2008 Mar; 62(3):444-9. PubMed ID: 18194278
[TBL] [Abstract][Full Text] [Related]
29. Efficacy, safety and potential clinical roles of the COX-2-specific inhibitors.
van der Bijl P; van der Bijl P
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):17-22. PubMed ID: 14552700
[TBL] [Abstract][Full Text] [Related]
30. Potential role of selective COX-2 inhibitors in cancer management.
Dang CT; Shapiro CL; Hudis CA
Oncology (Williston Park); 2002 May; 16(5 Suppl 4):30-6. PubMed ID: 12102578
[TBL] [Abstract][Full Text] [Related]
31. Cyclooxygenase-2 specific inhibitors in the treatment of dysmenorrhea.
Harel Z
J Pediatr Adolesc Gynecol; 2004 Apr; 17(2):75-9. PubMed ID: 15050982
[TBL] [Abstract][Full Text] [Related]
32. [COX and study of cancer therapy].
Yamada N; Ohira M; Hirakawa K
Gan To Kagaku Ryoho; 2004 Aug; 31(8):1147-51. PubMed ID: 15332534
[TBL] [Abstract][Full Text] [Related]
33. Polyamines and cancer: old molecules, new understanding.
Gerner EW; Meyskens FL
Nat Rev Cancer; 2004 Oct; 4(10):781-92. PubMed ID: 15510159
[TBL] [Abstract][Full Text] [Related]
34. Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer.
Liao Z; Milas L; Komaki R; Stevens C; Cox JD
Am J Clin Oncol; 2003 Aug; 26(4):S85-91. PubMed ID: 12902863
[TBL] [Abstract][Full Text] [Related]
35. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
[TBL] [Abstract][Full Text] [Related]
36. [Cyclooxygenase 2 inhibitors and urologic and gynaecologic cancers].
Eschwege P
Bull Cancer; 2004 May; 91 Spec No():S113-6. PubMed ID: 15239339
[TBL] [Abstract][Full Text] [Related]
37. Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo.
Johnsen JI; Lindskog M; Ponthan F; Pettersen I; Elfman L; Orrego A; Sveinbjörnsson B; Kogner P
Cancer Res; 2004 Oct; 64(20):7210-5. PubMed ID: 15492235
[TBL] [Abstract][Full Text] [Related]
38. Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?
Sanborn R; Blanke CD
Semin Oncol; 2005 Feb; 32(1):69-75. PubMed ID: 15726508
[TBL] [Abstract][Full Text] [Related]
39. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition.
Totzke G; Schulze-Osthoff K; Jänicke RU
Oncogene; 2003 Sep; 22(39):8021-30. PubMed ID: 12970750
[TBL] [Abstract][Full Text] [Related]
40. Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention.
Vanchieri C
J Natl Cancer Inst; 2005 Apr; 97(8):552-3. PubMed ID: 15840872
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
